ST PHARM News

Sep 6, 2024

ST Pharm to Present Basroparib (STP1002) at ESMO Congress 2024

ST Pharm is pleased to announce its participation in the ESMO Congress 2024, where we will present a poster session on Basroparib (STP1002), an innovative tankyrase inhibitor (TNKSi). This presentation will highlight the findings from a phase 1 clinical trial, marking a key development in cancer treatment.

Presentation Details:
  • Title: First-In-Human Dose-Escalation Study of Basroparib (STP1002) in Patients with Advanced-Stage Solid Tumors
  • Presentation Number: 633P
  • Poster Display Date: Saturday, September 14, 2024
  • On-Site Presentation Time: 12:00 PM - 1:00 PM
 
We invite attendees to visit our poster session to explore the promising results and advancements associated with Basroparib (STP1002).

For further information and to view the presentation schedule,
please visit: ESMO 2024 PresentationSchedule

For inquiries or additional information,
please contact us at stp.nddi@stpharm.co.kr.

We look forward to engaging with you at this prestigious event and sharing our latest research developments.